AORT ARTIVION, INC.
Surgical & Medical Instruments & Apparatus · NYSE · SEC CIK 784199 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY14.0%
TTM net income YoY-92.5%
TTM EPS YoY-56.5%
Revenue 3-yr CAGR12.4%
Net income 3-yr CAGR—
Margins
Gross margin63.3%
Operating margin2.3%
Net margin-3.7%
FCF margin-9.2%
EBITDA margin7.7%
Returns
ROE-4.0%
ROA-1.9%
ROIC (approx.)1.3%
Asset turnover0.51x
Leverage & solvency
Liabilities / assets57.2%
Debt / equity0.81x
Current ratio4.42x
Interest coverage0.41x
Cash quality & payout
Operating cash flow / net income-0.85x
Accruals ratio-3.4%
Payout ratio—
Capex / revenue12.3%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $441.33M | $388.54M |
| Cost of revenue | $157.10M | $139.76M |
| Gross profit | $284.23M | $248.78M |
| R&D expense | $30.99M | $28.45M |
| SG&A expense | $226.49M | $181.46M |
| Operating income | $33.74M | $38.87M |
| Interest expense | $26.58M | $34.28M |
| Pretax income | $14.78M | -$7.51M |
| Income tax | $5.01M | $5.84M |
| Net income | $9.77M | -$13.36M |
| EBITDA | $56.20M | $63.08M |
| EPS (basic) | 0.22 | -0.32 |
| EPS (diluted) | 0.21 | -0.32 |
| Weighted avg. shares (diluted) | 47.16M | 41.68M |
| Balance sheet | ||
| Cash & equivalents | $64.91M | $53.46M |
| Receivables | $89.76M | $79.46M |
| Inventory | $92.43M | $79.77M |
| Current assets | $358.08M | $290.08M |
| PP&E, net | $64.99M | $36.40M |
| Goodwill | $254.09M | $240.96M |
| Intangibles | $123.66M | $128.05M |
| Total assets | $884.80M | $789.10M |
| Current liabilities | $101.56M | $66.82M |
| Short-term debt | $0 | $195,000 |
| Long-term debt | $215.11M | $314.15M |
| Total debt | $215.11M | $314.35M |
| Total liabilities | $436.56M | $512.90M |
| Shareholders' equity | $448.23M | $276.20M |
| Net debt | $150.21M | $260.88M |
| Cash flow statement | ||
| Operating cash flow | $39.88M | $22.24M |
| Capital expenditure | $39.04M | $11.19M |
| Free cash flow | $839,000 | $11.05M |
| Investing cash flow | -$42.04M | -$28.19M |
| Financing cash flow | $11.28M | $2.20M |
| Depreciation & amortization | $22.46M | $24.20M |
| Stock-based compensation | $24.39M | $14.24M |
Free plan shows the latest 2 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.